Bonus Biogroup Announces U.S. Food and Drug Administration (FDA) Clearance of an Investigational New Drug (IND) Application for MesenCure™ Phase III Clinical Study in Respiratory Distress
The Company is working to expand its indication to include patients who have respiratory distress from any cause, including acute respiratory distress syndrome (ARDS) MesenCure's market potential in all-cause ARDS in the United States alone could reach approximately $9.6 billion by 2030, according to Company estimates TEL AVIV, Israel, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Bonus Biogroup (TASE: BONS), a late-stage biotechnology company priming immunomodulatory and regenerative mesenchymal stromal ce